Pharma manufacturing news in brief
pharmafile | September 6, 2011 | News story | Manufacturing and Production |Â Â pharma manufacturing newsÂ
USP expands operations in India, DSM gets green light for Chinese anti-infective joint venture, plus there are updates from CMC Biologics, Lonza, Roquette and DavosPharma/Advantar.
The US Pharmacopeial Convention (USP) has expanded a quality testing laboratory in Hyderabad, India, with an additional 86,000 sq.ft. of space and 20 additional staff members which will allow it to “do more collaborative testing, verification testing, pharmacopeial education, customer support and sourcing of written and physical stands for drugs”. USP said it would now be able to launch new initiatives in synthetic chemistry and bio-analytic chemistry and testing.
Royal DSM has been granted approval by antitrust authorities for its anti-infective manufacturing and supply joint venture with Chinese company Sinochem. Under the terms of the deal, the two firms will set up a Hong Kong-based unit called DSM Sinochem Pharmaceuticals that will make ingredients such as penicillin and cephalosporin antibiotics. Around 2,000 DSM employees will be transferred to the new company.
Contract biopharmaceutical manufacturing and development company CMC Biologics has completed the installation of a 2,000-litre single-use bioreactor unit at its manufacturing facility in Copenhagen, Denmark, and should complete its validation by the end of the year. The company said that adding the new reactor would help it meet increasing demand for late-stage clinical and commercial biologics supply.
Lonza has licensed its GS Gene Expression system to Oxford BioTherapeutics, which will use it to produce antibodies directed at a range of novel cancer targets. The agreement covers the research, development and commercial use of the GS system by Oxford BioTherapeutics and is subject to undisclosed payments and licence fees.
Excipient specialist Roquette has completed construction of a plant in Lestrem, France, which will be used to manufacture carbohydrate ingredients such as glucose and dextrose solutions for use in injectable drugs and dialysis solutions. The new plant replaces an earlier facility and production will be transferred to the new unit over the course of 2011.
US contract manufacturer DavosPharma has forged a non-exclusive strategic alliance with Advantar Laboratories, a contract laboratory provider of analytical and formulation development services. The two companies say they will work together to provide US-based biopharmaceutical clients with development, consultancy and programme management support for preclinical and clinical trial materials, as well as approved drugs and devices.
Phil Taylor
Related Content
Pharma manufacturing news in brief
Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates …
Bayer planning joint venture to make drugs in Russia
Germany’s Bayer AG has joined a number of its peers in the pharmaceutical industry with …
Pharma manufacturing news in brief
FDA sets aside $35m for manufacturing research, Anteco, Apicore and Vetter provide facility updates and …
